DUNAGIN PHARMACEUTICAL, INC. – Trademark Portfolio
Entity Type: 03
DUNAGIN PHARMACEUTICAL, INC. holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 9 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include GINGIMED, XYLIMIST, ARMUOR RX, NEUTRAMAXX, and KID'S CHOICE. The owner is based in Rogers, AR.
1506 N 2nd St
Rogers, AR 72757
Showing of trademarks Trademarks
Trademark Classifications
DUNAGIN PHARMACEUTICAL, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does DUNAGIN PHARMACEUTICAL, INC. have?
DUNAGIN PHARMACEUTICAL, INC. has 11 U.S. trademarks filed with the USPTO. Of these, 6 registered, 5 cancelled.
What trademark classes does DUNAGIN PHARMACEUTICAL, INC. file in?
DUNAGIN PHARMACEUTICAL, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are DUNAGIN PHARMACEUTICAL, INC.'s most well-known trademarks?
DUNAGIN PHARMACEUTICAL, INC.'s registered trademark portfolio includes well-known marks such as GINGIMED, XYLIMIST, ARMUOR RX, NEUTRAMAXX, and KID'S CHOICE. These are among 6 currently registered trademarks in the portfolio.
What is DUNAGIN PHARMACEUTICAL, INC.'s trademark registration success rate?
DUNAGIN PHARMACEUTICAL, INC. has a 55% trademark registration rate, with 6 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.